Research Topics
Genomes and Genes | B HemmerSummaryAffiliation: Philipps University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
New concepts in the immunopathogenesis of multiple sclerosisBernhard Hemmer
Department of Neurology, , Marburg 35033, Germany
Nat Rev Neurosci 3:291-301. 2002- The role of the polio virus receptor and the herpesvirus entry mediator B genes for the development of MSBerit Rosche
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Marburg, Germany Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
J Neuroimmunol 156:171-7. 2004..We did not find differences in the frequency of the polymorphisms or surface expression between MS patients and controls. Overall, our findings do not support a role of HVEB and PVR genes in the development of MS... - Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammationSabine Cepok
Neuroimmunology Group, Department of Neurology, Heinrich Heine-University, Moorenstr. 5, , Germany
J Neuroimmunol 180:33-9. 2006..These findings demonstrate a selective recruitment of IgM-IgD- memory B cells to the CSF suggesting a specific role of these cells during neuroinflammation... - Degeneracy in T-cell antigen recognition - implications for the pathogenesis of autoimmune diseasesB Hemmer
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Rudolf Bultmann Str 8, 35033, Marburg, Germany
J Neuroimmunol 107:148-53. 2000..Here we discuss recent findings on cross-recognition of T-cells and provide a new experimental approach to address specificity and cross-reactivity in autoimmune disorders... - [New approaches in research of therapy of multiple sclerosis]B Hemmer
Arbeitsgruppe für klinische Neuroimmunologie, Neurologische Klinik, Philipps Universitat Marburg
Med Klin (Munich) 96:23-8. 2001..Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system. With a prevalence of 0.1-0.15% in Germany multiple sclerosis is the most common cause of severe disability in young adults... - Pathogenesis of multiple sclerosis: an update on immunologyBernhard Hemmer
Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, 35033 Marburg, Germany
Curr Opin Neurol 15:227-31. 2002..In this paper we review recent progress and discuss the implications for new therapeutic strategies... - CD45 isoform expression in autoimmune myasthenia gravisB Tackenberg
Department of Neurology, Philipps University, Rudolf Bultmann Street 8, D 35033 Marburg, Germany
Autoimmunity 36:117-21. 2003..Since there is no other evidence for increased thymopoiesis in late-onset MG, we propose an altered subset balance in the circulation... - Impact of the Asp299Gly polymorphism in the toll-like receptor 4 (tlr-4) gene on disease course of multiple sclerosisA Kroner
Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius Maximilians Universität Würzburg, Josef Schneider Str 11, 97080 Wurzburg, Germany
J Neuroimmunol 165:161-5. 2005..01). However, these functional changes seem not to have any impact on the clinical presentation of MS patients with different TLR-4 genotypes... - Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosisS Cepok
Clinical Neuroimmunology Group, Department of Neurology, Philipps-University, Marburg, Germany
Brain 124:2169-76. 2001..Our study demonstrates the existence and potential clinical relevance of different CSF cytology patterns. We hypothesize that CSF cytology patterns may reflect the heterogeneity in the pathogenesis of multiple sclerosis... - New approaches to dissect degeneracy and specificity in T cell antigen recognitionM Jacobsen
Clinical Neuroimmunology Group, Department of Neurology, Philipps-University, Rudolf-Bultmann Strasse 8, 35033 Marburg, Germany
J Mol Med 79:358-67. 2001..Here, we summarize recent progress on T cell recognition and method innovations with respect to future studies in autoimmune diseases... - Analysis of the monocyte chemoattractant protein 1 -2518 promoter polymorphism in patients with multiple sclerosisA Kroner
Bayerische Julius Maximilians Universität, Department of Neurology, Wurzburg, Germany
Tissue Antigens 64:70-3. 2004..Thus, our data could not reveal any association between the MCP-1 -2518 polymorphism and susceptibility to or clinical disease course of MS... 
Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosisA Chan
Department of Neurology, Ruhr University, St Josef Hospital, Bochum, Germany
Mult Scler 16:1189-92. 2010..The proposed predictive value of serum anti-myelin antibodies for the development of multiple sclerosis after a first clinically isolated syndrome was recently challenged...- No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosisD Schweer
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Rudolf Bultmann Str 8, 35033, Marburg, Germany
J Neuroimmunol 118:300-3. 2001..Furthermore, no differences in serum A2M levels were detected between MS patients and controls. The results do not suggest a contribution of A2M and LRP to the development of MS... - The p150 subunit of dynactin (DCTN1) gene in multiple sclerosisC Munch
Department of Neurology, Jewish Hospital, Berlin, Germany
Acta Neurol Scand 116:231-4. 2007..Given the common features of neurodegeneration in multiple sclerosis (MS), FTD and ALS, sequence variants of the DCTN1 gene may be a contributory factor to neurodegeneration in MS... - Immunosuppressive treatment of ocular myasthenia gravisB Tackenberg
Clinical Neuroimmunology Group, Department of Neurology, Philipps-University, Rudolf-Bultmann-Strasse 8, D-35033 Marburg, Germany
BioDrugs 15:369-78. 2001.... - Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MSM C Kowarik
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Neurology 76:1214-21. 2011..The effects of fingolimod treatment on the CSF of patients with MS have not been studied so far... - Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseasesR C Selter
Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Strasse, Munich, Germany
Neurology 74:1711-5. 2010..The relation between antibody responses to EBV and nMOG has not been addressed in children so far... - A point mutation in PTPRC is associated with the development of multiple sclerosisM Jacobsen
Department of Neurology, Philipps University, Marburg, Germany
Nat Genet 26:495-9. 2000..Our findings suggest an association of the mutation in PTPRC with the development of MS in some families... - NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsySebastian Bauer
Department of Neurology, University of Marburg, Rudolf Bultmann Str 8, 35033 Marburg, Germany
Exp Neurol 211:370-7. 2008..Immunological phenomena may affect the course of focal epilepsy. We analyzed prospectively the pre- and postictal distribution of leukocyte subsets in epileptic patients... - Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitmentMarkus Krumbholz
Department of Neuroimmunology, Max Planck Institute of Neurobiology, Martinsried, Germany
Brain 129:200-11. 2006..Therefore, both CXCL13 and CXCR5 may be promising therapeutic targets in multiple sclerosis... - Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosisOlaf Stuve
Department of Neurology, University of Texas Southwestern Medical Center at Dallas, USA
Arch Neurol 63:1383-7. 2006.... 
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosisDun Zhou
Department of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
Proc Natl Acad Sci U S A 103:19057-62. 2006..Overall these findings suggest a pathogenic antibody response to native MOG in a subgroup of MS patients...- Clonal expansions of CD4+ B helper T cells in autoimmune myasthenia gravisBjörn Tackenberg
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Marburg, Germany
Eur J Immunol 37:849-63. 2007..Thus, our data provide evidence for persistent clonally expanded CD4+ B helper T cell populations in the blood of MG patients. These unexpected CD4+ expansions might hold valuable clues to MG immunopathogenesis... - Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist--a putative role for substance P in CNS inflammationStefan Nessler
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, Marburg, Germany
J Neuroimmunol 179:1-8. 2006..In summary, our findings suggest that the protective effect of CP96,345 treatment is mediated by stabilization of the blood-brain barrier and suppression of Th1 immunity... - Acute disseminated encephalomyelitis: an acute hit against the brainTil Menge
Department of Neurology, Heinrich Heine University of Dusseldorf, Germany
Curr Opin Neurol 20:247-54. 2007..ADEM is a para- or postinfectious autoimmune demyelinating disease of the central nervous system and has been considered a monophasic disease. The highest incidence of ADEM is observed during childhood... - Immunopathogenesis and immunotherapy of multiple sclerosisBernhard Hemmer
Neuroimmunology Group, Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Nat Clin Pract Neurol 2:201-11. 2006..Here, we review current knowledge of the immunopathogenesis of MS and corresponding animal models of disease, and discuss new immunointerventional treatment strategies based on changing pathogenetic concepts... - Treatment and treatment trials in multiple sclerosisBernd C Kieseier
Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
Curr Opin Neurol 20:286-93. 2007..This review focuses on advances in current and novel treatment approaches in multiple sclerosis... - Neutralising antibodies to interferon beta in multiple sclerosis : expert panel reportHans P Hartung
Dept of Neurology, Heinrich Heine University, Moorenstrasse 5, 40225, Dusseldorf, Germany
J Neurol 254:827-37. 2007.... - HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosisSteve Hoffmann
Department of Bioinformatics, Interdisciplinary Center for Bioinformatics, University Leipzig, Leipzig, Germany
Am J Hum Genet 83:219-27. 2008..In summary, we identified genetic factors determining the immunogenicity of IFN-beta, a protein-based disease-modifying agent for the treatment of MS... - Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosisElke Wiesemann
Department of Neurology, Medical School Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
Clin Immunol 128:306-13. 2008..The results suggest that serum IL-10 is useful to predict treatment response to IFN-beta particularly in combination with a panel of other IFN-beta dependent parameters... - Pharmacological treatment of early multiple sclerosisOlaf Stuve
Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA
Drugs 68:73-83. 2008.... - Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Bernhard Hemmer
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Ann Neurol 62:314-26. 2007..Future treatments will likely need both to target inflammation and to focus on promotion of neuroprotection and repair. In this review, we discuss the most promising therapeutic approaches for MS currently in the pipeline... - Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosisElke Wiesemann
Department of Neurology, Medical School Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
Mult Scler 14:166-76. 2008..Upregulation of the expression of CD40, CD86 and PD-L2 may be useful as a predictive marker for clinical response to IFN-beta treatment at early timepoints during IFN-beta therapy... - Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damageStefan Nessler
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Brain 130:2186-98. 2007..Taken together, MRI of mouse EAE models with brain lesions provide new insights into lesion pathology and evolution and may prove useful for the in vivo assessment of new therapeutic strategies in MS... - Impact of HMG-CoA reductase inhibition on brain pathologyFrauke Zipp
Cecilie Vogt Clinic for Molecular Neurology, Charite Universitaetsmedizin Berlin, and Max Delbrueck Center for Molecular Medicine, 10117 Berlin, Germany
Trends Pharmacol Sci 28:342-9. 2007.... - Central nervous system infections - a potential complication of systemic immunotherapyBernhard Hemmer
Department of Neurology, Heinrich Heine University, , Germany USA
Curr Opin Neurol 19:271-6. 2006..One possible outcome is an increased incidence of opportunistic infections. A heightened vigilance for central nervous system infections in the setting of immunosuppression is necessary to prevent serious side-effects in the future... - Immune surveillance in multiple sclerosis patients treated with natalizumabOlaf Stuve
Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, USA
Ann Neurol 59:743-7. 2006.... - Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunityOlaf Stuve
Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, USA
J Clin Invest 116:1037-44. 2006..Our results demonstrate that agents with different mechanisms of immune modulation can combine in a synergistic manner for the treatment of CNS autoimmunity and provide rationale for testing the combination of atorvastatin and GA in MS... - Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosisSabine Cepok
Department of Neurology, Heinrich Heine-University, Duesseldorf, Germany
Brain 128:1667-76. 2005..This study identifies short-lived plasma blasts as the main effector B cell population involved in ongoing active inflammation in multiple sclerosis patients... - Viral pathogens in multiple sclerosis: an intriguing (hi)storyOlaf Stuve
Arch Neurol 61:1500-2. 2004 - Myositis in a patient with large granular leukocyte leukemiaBerit Rosche
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, Marburg 35033, Germany
Muscle Nerve 29:873-7. 2004..The immunological phenotype of the patient and the positive response to treatment adds further to the concept that CD8(+) T cells mediate disease in autoimmune myositis... - Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluidLorenz C Hofbauer
Acta Neuropathol 107:575-7, author reply 578. 2004 - Specificity and degeneracy: T cell recognition in CNS autoimmunityDun Zhou
Clinical Neuroimmunology Group, Department of Neurology, Philipps-University, Rudolf-Bultmann Strasse 8, 35033 Marburg, Germany
Mol Immunol 40:1057-61. 2004.... - The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitisSabine Cepok
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Marburg, Germany
Arch Neurol 60:849-55. 2003.... - New immunopathologic insights into multiple sclerosisBernhard Hemmer
Department of Neurology, , Moorenstrasse 5, , Germany
Curr Neurol Neurosci Rep 3:246-55. 2003..We review the role of the immune system for the manifestation and evolution of MS and discuss different pathogenetic concepts. We conclude with an outlook on future strategies to identify the cause of MS... - A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 moleculeMarc Jacobsen
Department of Neurology, Philipps University, Rudolf Bultmann Strasse 8, 35033 Marburg, Germany
Immunogenetics 54:158-63. 2002..Overall, we describe the first mutation in PTPRCthat interferes with splicing and results in surface expression of a structurally altered CD45 molecule in humans... - Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosisSabine Cepok
Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
J Clin Invest 115:1352-60. 2005..In summary, these findings demonstrate an increased immune response to EBV in MS patients, which suggests that the virus plays an important role in the pathogenesis of disease... - Multiple sclerosis--novel insights and new therapeutic strategiesBernd C Kieseier
Curr Opin Neurol 18:211-20. 2005..In various animal models cell-replacement strategies yield promising results; however, turning these findings into an effective therapy in MS patients has a long way to go... - Multiple sclerosis and the autonomic nervous systemStefan Merkelbach
Dept of Neurology, HELIOS Klinikum, Nordhauser Str 74, 99089, Erfurt, Germany
J Neurol 253:I21-5. 2006..Beside these clinical aspects, alterations of the autonomic nervous system have also been reported to alter immunological cascades in experimental conditions. However, corresponding results have not been confirmed in clinical trials yet... - Acute disseminated encephalomyelitis: an updateTil Menge
Department of Neurology, University of San Francisco, San Francisco, Calif, USA
Arch Neurol 62:1673-80. 2005.... - Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosisHans Peter Hartung
Neurologische Klinik, Heinrich Heine Universitat Dusseldorf, Moorenstrasse 5, 40225, Dusseldorf, Germany
J Neurol 252:v30-7. 2005..All have been shown to reduce the number of gadolinium-enhancing T1 lesions observed with magnetic resonance imaging, an index of acute inflammatory invasion of the central nervous system... - Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosisOlaf Stuve
Department of Neurology and Institute of Diagnostic Radiology, Heinrich Heine University, Dusseldorf, Germany
Arch Neurol 62:1620-3. 2005..A limited effect of rituximab on B lymphocytes in the cerebrospinal fluid compartment of patients with primary progressive multiple sclerosis (MS) was recently reported... - Multiple sclerosis -- a coordinated immune attack across the blood brain barrierBernhard Hemmer
Heinrich Heine Universitat, MNR Klinik Geb 13 53, Klinik fur Neurologie, Moorenstrasse 5, 40225 Dusseldorf, Germany
Curr Neurovasc Res 1:141-50. 2004..Based on these considerations we discuss new strategies to investigate pathogenetic pathways in multiple sclerosis... - Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitroOliver Neuhaus
Department of Neurology, Heinrich Heine Universitat, Moorenstr 5, 40225 Dusseldorf, Germany
J Neuroimmunol 168:128-37. 2005.... - High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosisSilva Markovic-Plese
Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
J Neuroimmunol 169:31-8. 2005..The results have implications for vaccine design and for antigen-specific treatment strategies for autoimmune diseases... - Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosisBernhard Hemmer
Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
Lancet Neurol 4:403-12. 2005..Strategies to assess and manage the long-term impact of neutralising antibodies will be outlined... - A PD-1 polymorphism is associated with disease progression in multiple sclerosisAntje Kroner
Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, Bayerische Julius Maximilians Universität, Wurzburg, Germany
Ann Neurol 58:50-7. 2005..In conclusion, our data suggest that PD-1 polymorphism is a genetic modifier of the progression of MS, possibly through inducing a partial defect in PD-1-mediated inhibition of T-cell activation... - Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patientsMarc Jacobsen
Clinical Neuroimmunology Group, Department of Neurology, Philipps University, Rudolf-Bultmann Strasse 8, 35033 Marburg, Germany
Brain 125:538-50. 2002..Our study provides a basis for future trials to identify disease-associated antigens and disease pathogenesis in multiple sclerosis...